BrightPath Biotherapeutics Co., Ltd
4594・Growth Market・Pharmaceuticals
Governance
The company has a Board of Corporate Auditors (4 directors, including 1 outside director; 3 outside corporate auditors). The Board of Directors meets at least once a month, with all directors attending all 12 meetings held during the year. Neither a Nomination Committee nor a Compensation Committee has been established.
Risk Management
In accordance with the Risk Management Regulations, the Company has established a Risk Management Committee (comprised of the President, directors responsible for each department, and general managers) that reports directly to the President, and conducts risk identification and classification on a quarterly basis. Deliberation results are reported to the Board of Directors, and a framework has been established for formulating countermeasures and recurrence prevention measures.
Shareholder Returns
No dividend continued in FY2026 (ending March 2026) (annual dividend of ¥0). No dividend forecast for FY2027 (ending March 2028) as well. Priority is given to securing R&D funding, with a policy of retaining internal reserves for the time being. Share buybacks in the current period were limited to a single share (acquisition expenditure of ¥1 thousand), representing no substantive shareholder return track record.
Dividend Policy
The company has not paid dividends since its founding, and the annual dividend for FY2026 (ending March 2026) is ¥0. The forecast for FY2027 (ending March 2028) is also ¥0. The company is not currently in a position to pay dividends, and since it plans to conduct R&D activities involving substantial upfront investment in a planned manner going forward, it intends to focus on retaining internal reserves for the time being to prioritize securing R&D funding. If dividends are paid, they are expected to be a single year-end dividend per year, with the decision-making body being the general shareholders' meeting.
ESG
The company positions R&D of cancer immunotherapies as the core of its business, aligned with SDG Goal 3 ("Good Health and Well-being for All"). While climate change is not currently recognized as a materially significant issue—efforts are limited to paperless initiatives and energy/water conservation—on the human capital side, the company promotes the creation of a "comfortable workplace" through mid-career hiring, recruitment of young talent, harassment prevention training, and promotion of flexible working styles, though quantitative KPIs and targets have not yet been established.
Last updated: June 25, 2026